

Non-Alcoholic Steatohepatitis Therapeutic Pipeline Market Review, H2 2016

Non-Alcoholic Steatohepatitis Treatment Pipeline Review H2 2016

PUNE, INDIA, October 21, 2016

/EINPresswire.com/ -- The report

provides comprehensive information on the therapeutics under

development for [Non-Alcoholic](#)

[Steatohepatitis](#), complete with analysis

by stage of development, drug target,

mechanism of action (MoA), route of

administration (RoA) and molecule

type. The report also covers the

descriptive pharmacological action of

the therapeutics, its complete research and development history and latest news and press

releases. Additionally, the report provides an overview of key players involved in therapeutic

development for Non-Alcoholic Steatohepatitis and features dormant and discontinued

projects.



Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619306-non-alcoholic-steatohepatitis-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
- The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Non-Alcoholic Steatohepatitis Overview 12

Therapeutics Development	13
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview	13
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis	14
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies	15
Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes	20
Non-Alcoholic Steatohepatitis - Pipeline Products Glance	21
Late Stage Products	21
Clinical Stage Products	22
Early Stage Products	23
Unknown Stage Products	24
Non-Alcoholic Steatohepatitis - Products under Development by Companies	25
Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes	31
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development	32
Akarna Therapeutics Ltd.	32
AlbireoPharma	33
Alnylam Pharmaceuticals, Inc.	34
Amunix Operating Inc.	35
Aquinox Pharmaceuticals Inc.	36
Arisaph Pharmaceuticals, Inc.	37
AstraZeneca Plc	38
BiOrion Technologies B.V.	39
Bird Rock Bio, Inc.	40
Boehringer Ingelheim GmbH	41
Bristol-Myers Squibb Company	42
Can-Fite BioPharma Ltd.	43
Cardax Pharmaceuticals, Inc.	44
Catabasis Pharmaceuticals, Inc.	45
Cerenis Therapeutics Holding SA	46
Conatus Pharmaceuticals Inc.	47
Connexios Life Sciences Pvt. Ltd.	48
Daiichi Sankyo Company, Limited	49
DURECT Corporation	50
Dynavax Technologies Corporation	51
Eli Lilly and Company	52
Enanta Pharmaceuticals, Inc.	53
Exicure, Inc.	54
Galectin Therapeutics, Inc.	55
Galmed Pharmaceuticals Ltd.	56
Genextra S.p.a.	57
Genfit SA	58
GenKyoTex S.A.	59
Gilead Sciences, Inc.	60
GRI Bio, Inc.	61

iCo Therapeutics Inc. 62

Immuron Limited 63

Access Report @ <https://www.wiseguyreports.com/reports/619306-non-alcoholic-steatohepatitis-pipeline-review-h2-2016> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/350393978>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.